Tislelizumab plus chemotherapy significantly extends OS in advanced esophageal cancer

The addition of tislelizumab to chemotherapy significantly extended OS for patients with previously untreated advanced esophageal squamous cell carcinoma, according to a press release from the agent’s manufacturer.The combination conferred the survival benefit among patients with unresectable, locally advanced, recurrent or metastatic disease regardless of PD-L1 expression, an interim analysis of the randomized phase 3 RATIONALE 306 study showed. It also had a safety profile consistent with that observed in previous trials.“We are encouraged by the survival benefit seen in theRead More

Related Articles